Israel - English - Ministry of Health

sanofi israel ltd - thyrotropin alfa - powder for solution for injection - thyrotropin alfa 0.9 mg/ml - thyrotropin - thyrotropin - adjunctive diagnostic tool for serum thyroglobulin (tg) testing with or without radioiodine imaging in the follow up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.

Israel - English - Ministry of Health

sanofi israel ltd - agalsidase beta - powder for concentrate for solution for infusion - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

Israel - English - Ministry of Health

sanofi israel ltd - dupilumab - solution for injection - dupilumab 150 mg/ml - dupilumab - atopic dermatitisdupixent is indicated for the treatment of treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (ad) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. dupixent can be used with or without topical corticosteroids.asthmadupixent is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.limitation of usedupixent is not indicated for the relief of acute bronchospasm or status asthmaticus. chronic rhinosinusitis with nasal polyposisdupixent 300mg is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (crswnp).eosinophilic esophagitisdupixent is indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (eoe).prurigo nodularisdupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy.

Israel - English - Ministry of Health

sanofi israel ltd - dupilumab - solution for injection - dupilumab 175 mg/ml - dupilumab - atopic dermatitis dupixent is indicated for the treatment of treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (ad) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. dupixent can be used with or without topical corticosteroids. asthma dupixent is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. limitation of use: dupixent is not indicated for the relief of acute bronchospasm or status asthmaticus.

Israel - English - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 33 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors

Israel - English - Ministry of Health

sanofi israel ltd - dronedarone - film coated tablets - dronedarone 400 mg - dronedarone - dronedarone - multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (af). due to its safety profile, multaq should only be prescribed after alternative treatment options have been considered.multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.

Israel - English - Ministry of Health

sanofi israel ltd - rabies, inactivated, whole virus - powder and solvent for suspension for injection - rabies, inactivated, whole virus 2.5 iu - rabies, inactivated, whole virus - rabies, inactivated, whole virus - prevention of rabies in children and adults. it can be used before and after exposure, as a primary vaccination or as a booster dose.

Israel - English - Ministry of Health

sanofi israel ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - solution for injection - meningococcal vaccines group c 4 mcg / 0.5 ml; meningococcal vaccines group y 4 mcg / 0.5 ml; meningococcal vaccines group w 4 mcg / 0.5 ml; meningococcal vaccines group a 4 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y, and w-135 menactra vaccine does not prevent n meningitidis serogroup b disease.

Israel - English - Ministry of Health

sanofi israel ltd - hydroxychloroquine sulfate - film coated tablets - hydroxychloroquine sulfate 200 mg - hydroxychloroquine - hydroxychloroquine - plaquenil is indicated for the suppressive treatment and treatment of acute attacks of malaria due to plasmodium vivax, p. malaria. p. ovale and susceptible strains of p. falciparum it is also indicated for the treatment of discoid and sustemic lupus erythematosus and rheumatoid arthritis.

Israel - English - Ministry of Health

sanofi israel ltd - ramipril - tablets - ramipril 1.25 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.